期刊文献+

液相色谱-串联质谱法测定人血清中苯磺酸氨氯地平的浓度 被引量:9

Determination of amlodipine besylate in human serum by LC-MS/MS method
下载PDF
导出
摘要 目的:建立测定体内苯磺酸氨氯地平的液相色谱-串联质谱(LC-MS/MS)方法。方法:血清样品中加入内标苯海拉明,直接沉淀蛋白法处理样品。色谱柱为Atlantis C_(18)(100 mm×2.1 mm,3μm),流动相为含0.1%甲酸的乙腈-0.1%甲酸水溶液(42:58,V:V),流速为0.25 mL·min^(-1)。MRM扫描分析,苯磺酸氨氯地平和内标苯海拉明的离子通道分别选择为m/z 409.1→238.1和256.3→167.0。结果:苯磺酸氨氯地平的线性范围为0.2~32μg·L^(-1),最低定量限为0.2μg·L^(-1),提取回收率均大于95%,日内、日间RSD均小于15%。结论:本方法灵敏、准确、专一、操作简便,适用于苯磺酸氨氯地平的体内药动学研究。 AIM: To develop a LC-MS/MS method for determination of amlodipine besylate in human serum. METHODS: After addition of diphenhydramine (internal standard, IS), the analyte was isolated by protein precipitation. The chromatographic separation was performed on Atlantis C18 (100 mm × 2.1 mm, 3 μm) column with a mobile phase of 0.1% formic acid acetonitrile-0.1% formic acid water (42 : 58, V : V) at a flow rate of 0.25 mL. min^-1. The deprotonated ion of analyte was detected in negative ionization by multiple reaction monitoring mode (MRM). The mass transition pairs of m/z 409.1→238.1 and m/z 256.3→167.0 were used to detect amlodipine besylate and internal standard, respectively. RESULTS: The calibration curves were linear over the ranges of 0.2-32 μg. L^-1. The lower limit of quantification was 0.2 μg. L^-1. The extraction recovery was more than 95 %. The intra-day RSD and inter-day RSD were less than 15 %. CONCLUSION: The method is sensitive, accurate, convenient and suitable for the pharmacokinetic study of amlodipine besylate tablets.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2007年第10期737-740,共4页 Chinese Journal of New Drugs and Clinical Remedies
关键词 氨氯地平 色谱法 高压液相 光谱法 质量 电喷雾电离 药动学 amlodipine chromatography, high pressure liquid spectrometry, mass, electrospray ionization pharmacokinetics
  • 相关文献

参考文献5

二级参考文献9

  • 1陆佩荣,毕秀玲,谢玉芝.络活喜片含量均匀度测定方法的改进[J].药物分析杂志,1995,15(4):42-43. 被引量:2
  • 2史晏海,凌华伟.新型钙离子拮抗剂氨氯地平[J].中国新药杂志,1995,4(5):9-12. 被引量:19
  • 3TULENKO TN, SUMNER AE, CHEN M, et al. The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection[J]. Am Heart J, 2001, 141 (2Suppl) :S1-S11. 被引量:1
  • 4UESHIBA H, MIYACHI Y. Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients[J]. Intern Med, 2004, 43(7):561-565. 被引量:1
  • 5FLYNN JT. Efficacy and safety of prolonged amlodipine treatment in hypertensive children[J]. Pediatr Nephrol, 2005, 20(5):631-635. 被引量:1
  • 6ROJANASTHIEN N, TEEKACHUNHATEAN S, JAKOB K, et al. Bioequivalence study of amlodipine in healthy Thai male volunteers[J]. Int J Clin Pharmacol Ther, 2004, 42(6):330-335. 被引量:1
  • 7CARVALHO M, OLIVEIRA CH, MENDES GD, et al. Amlodipine bioequivalence study: quantification by liquid chromatography coupled to tandem mass spectrometry[J]. Biopharm Drug Dispos, 2001, 22(9):383-390. 被引量:1
  • 8GANAFA A A, WALTON M, EATMAN D, et al. Amlodipineatte nuates oxidative stress-induced hypertension[J]. Am J Hypertens,2004, 17(9) :743-748. 被引量:1
  • 9张荷,刘坤申,高仁果,刘超,薛红元.左旋氨氯地平和氨氯地平对高血压病人内皮功能及血清胆固醇影响[J].中国新药与临床杂志,2003,22(6):337-340. 被引量:29

共引文献9

同被引文献68

引证文献9

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部